Planned and previous talks, presentations and workshops from the ADMC Consortium over the past three years
February 3-8 Gordon Research Conference: Metabolomics and Human Health, Venture, CA
- Shotgun Lipidomics Sheds Light on Alzheimer’s Disease: Implying the Importance of Standardization and Quantification in Lipidomics. Xianlin Han, University of Texas Health Science Center at San Antonio
- Metabolomics, Metabolism, and Time. Gabi Kastenmüller, Helmholtz Zentrum München, Germany
- Exploring Host-Microbiome Co-Metabolism Through Metabolic Modeling. Ines Thiele, National University of Ireland – Galway
- Profiling Bile Acids to Understand Their Metabolic Role in Alzheimer’s Disease. Priyanka Baloni, Institute for Systems Biology
- Integrative Metabolomics in Alzheimer’s Disease: Enabling Precision Medicine by Disease Sub-classification. Matthias Arnold, Helmholtz Zentrum München, Germany
July, 22-26 2018 Alzheimer’s Association International Conference 2018, Chicago, IL
Basic and Translational Science Session Gut-Liver-Brain Axis in Alzheimer’s Disease Co-chairs: Rima Kaddurah-Daouk, Duke University and Cornelia van Duijn, Leiden University Leiden, Netherlands
• Altered Bile Acid Metabolites in Mild Cognitive Impairment and Alzheimer’s Disease: Relation to Neuroimaging and CSF Biomarkers, Kwangsik Nho, et al. e Indiana University School of Medicine, Indianapolis, IN. Abstract/Proposal ID# 26438
• Circulating Metabolites Association with Alzheimer’s Disease Associated Genetic Variants, Shahzad Ahmad, et al. Erasmus University Medical Center, Rotterdam, Netherlands. Abstract/Proposal ID# 26440
• Association of Serum Lipids with Alzheimer Disease in the Adni Cohort- an Untargeted Lipidomics Study, Dinesh Kumar Barupal, et al. NIH-West Coast Metabolomics Center, Davis, CA. Abstract/Proposal ID# 26442
• Serum Indices of Ethanolamine Plasmalogens and Phosphatide Metabolism in the Combined Adni-1/GO/2 Cohort: Does the Liver Contribute to AD Risk By Failing to Supply Key Lipids to the Brain?, Mitchel A. Kling, et al. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Abstract/Proposal ID# 26446
June, 24-28 2018 Metabolomics Society Conference, Seattle, WA
Workshop: Metabolomics Enabling Tools for Precision Medicine Organizer: Rima Kaddurah-Daouk, Duke University
March 1-2, 2018 NIH Alzheimer’s Research Summit: Path to Treatment and Prevention, Bethesda, MD.
Enabling Precision Medicine for AD Session Two co-chairs: David Bennett, Rush University and Rima Kaddurah-Daouk, Duke University.
• Integrative Metabolomics: From Target Discovery to Disease Sub-Classification, Matthias Arnold, Institute for Bioinformatics and Systems Biology, Munich.
Nov, 29-30 2017 Understanding the Role of the Microbiome in Aging and Age-Related Disorders: Implications for Disease Treatment and Prevention, Rockville, MD.
• Role of the Microbiome in AD: Signals from Clinical Research. Rima Kaddurah-Daouk, Duke University
Nov, 7 2017 NIA M2OVE AD Consortium F2F Meeting, Bethesda, MD.
• Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-Type Dementias. Rima Kaddurah-Daouk, Duke University and Mitch Kling, University of Pennsylvania
July, 16-17 2017 Alzheimer’s Association International Conference 2017
Featured Research Session #3123 Session Chair: Rima Kaddurah-Daouk, Duke University
F2-01 Metabolomics and Systems Approach Reveals That Peripheral Metabolism Is Central in Alzheimer Disease
• Genomics and Imaging Data Informed Metabolomics – a Biochemical Roadmap for Alzheimer Disease. Featured Research Session #18575
• Gut Derived Bile Acid Metabolites Correlate with Structural and Functional Neuroimaging Measures in Alzheimer’s Disease. Featured Research Session #18572
F1-02 Combinatorial Biomarkers for Alzheimer’s Disease – Huge, but Challenging, Opportunity.
• Integrating Multi-Modality Imaging and Multi-Layer -Omics to Advance the Systems Biology of Alzheimer’s Disease. Featured Research Session #16825
July, 11-12 2017 NIA AMP AD Target Discovery and Preclinical Validation Consortium F2F Meeting, Bethesda, MD.
• Multiplatform lipidomics analysis. Rebecca Baillie, Duke University
• Integrative metabolomics for validation of AMP-AD candidate targets. Matthias Arnold, Duke University/Institute for Bioinformatics and Systems Biology, Munich.
Jun 22, 2017 Biocrates Targeted Metabolomics Workshop and User Meeting I Duke University GCB
• The Alzheimer’s Disease Metabolomics Consortium. Rima Kaddurah-Daouk, Duke University
Nov 28-29, 2016 AMP-Alzheimer’s Disease Annual F2F Meeting Bethesda, MD.
• The Gut-Liver-Brain Axis in Alzheimer Disease – a new role for the gut microbiome. Rebecca Baillie, Rosa & Co.
• Partial correlation networks filling biochemical gap of knowledge about Alzheimer Disease. Matthias Arnold, Helmholtz Zentrum München
• Interrogating Metabolome Genome Links to Inform Target Selection. Gabi Kastenmüller, Helmholtz Zentrum München
July, 24 2016 Alzheimer’s Association International Conference 2016. Toronto, ON, CAN
Featured Research Session #2123 Session Chair: Rima Kaddurah-Daouk, Duke University
F1-02 Metabolic Pathway and Network Failures in Alzheimer’s Disease,
• The Alzheimer’s Metabolome: Relationship to Pathological Markers and Cognitive Decline in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Jon B. Toledo, et al. Featured Research Session #9459
• Genetic Influence on Levels of Targeted Metabolites Associated with Alzheimer’s Disease. Sungeun Kim, et al. Featured Research Session #9355
• Metabolites Associated with Cognitive Function in the Rotterdam Study and Erasmus Rucphen Family Study. Cornelia M van Duijn et al. Featured Research Session #9356
• Plasma Phosphatidylcholines Are Associated with Alzheimer’s Disease As Well As Brain Function and Cognitive Performance during Aging. Madhav Thambisetty, et al. Featured Research Session #9458
P3-09 [Posters Tues] PIA: Blood-Based Biomarkers
• Indices of Plasmalogen Biosynthesis in Adni-1 Baseline Serum Samples: Association with Progression to Dementia in Subjects with Mild Cognitive Impairment. Poster #11704
June 27-30, 2016 Metabolomics Society Conference, Dublin, Ireland
• Pharmacometabolomics: Enabling Tool for Precision Medicine. Rima Kaddurah-Daouk, Duke University. #2591
June 8-9, 2016 AMP AD Target Discovery and Preclinical Validation Consortium F2F Meeting, Bethesda, MD.
• Metabolic Networks and Pathways in AD. Rima Kaddurah-Daouk, Duke University